Accéder au contenu
Merck

O7125

L-Ornithine L-aspartate salt

≥98% (TLC)

Synonyme(s) :

(S)-2,5-Diaminopentanoic acid L-aspartate salt

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Le tarif et la disponibilité ne sont pas disponibles actuellement.

A propos de cet article

Formule empirique (notation de Hill) :
C9H19N3O6
Numéro CAS:
Poids moléculaire :
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:

Passer à

Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

L-Ornithine L-aspartate salt, powder

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

assay

≥98% (TLC)

form

powder

color

white to off-white

storage temp.

2-8°C

Quality Level

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
O2375O438675490
form

powder

form

powder

form

powder

form

powder

assay

≥98% (TLC)

assay

≥99%

assay

≥99%

assay

≥99.0% (AT)

storage temp.

2-8°C

storage temp.

-

storage temp.

-

storage temp.

-

color

white to off-white

color

white

color

white

color

-

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

100

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

Classe de stockage

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Shahab Abid et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21(11), 666-671 (2011-11-15)
To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). Randomized placebo controlled study. The Aga Khan University Hospital, Karachi in the year 2003-2004. Patients with HE were randomized to receive LOLA
Imre Fehérvári et al.
Magyar sebeszet, 65(2), 58-62 (2012-04-20)
About 6500-7000 people/year die in Hungary due to liver cirrhosis which is often complicated with hepatic encephalopathy (HE). While conventional interpretation is that hepatic encephalopathy is a consequence of high blood ammonia level, recent data indicate that the degree of
José Luis Pérez Hernández et al.
Annals of hepatology, 10 Suppl 2, S66-S69 (2012-01-18)
Introduction. Hepatic encephalopathy (HE) refers to a complex neuropsychiatric syndrome that is progressive but potentially reversible and may have a significant impact on quality of life, as it is characterized by alterations in cognitive function, behavior and personality as well
Takeyori Saheki et al.
Scientific reports, 9(1), 4179-4179 (2019-03-14)
Previous studies using citrin/mitochondrial glycerol-3-phosphate (G3P) dehydrogenase (mGPD) double-knockout mice have demonstrated that increased dietary protein reduces the extent of carbohydrate-induced hyperammonemia observed in these mice. This study aimed to further elucidate the mechanisms of this effect. Specific amino acids
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique